Adalimumab induced psoriasis in a Crohn's disease patient: A case report

被引：0
作者：
Alenizi, Dhaifallah [1 ]
机构：
[1] Northern Border Univ, Dept Dermatol, Ar Ar, Saudi Arabia
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 07期
关键词：
Adalimumab; psoriasis; Crohn's disease; paradoxical psoriasis; INDUCTION;
D O I：
10.47391/JPMA.9817
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Adalimumab is a human monoclonal antibody that selectively targets tumour necrosis factor -alpha (TNF- alpha), a cytokine involved in the pathogenesis of various inflammatory and autoimmune disorders. Adalimumab has been approved worldwide for the treatment of several chronic immune -mediated diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. One of the adverse reactions caused by Adalimumab is psoriasis. This study reports the case of a 37 -year -old male with palmoplantar psoriasis triggered by adalimumab for treatment of Crohn's disease. This eruption resisted complete clearance with various potent corticosteroids. The patient was referred back to the treating rheumatologist to possibly change adalimumab to another type of therapy.
引用
收藏
页码：1361 / 1363
页数：3
相关论文
共 11 条
  • [1] Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
    Burmester, G. R.
    Mease, P.
    Dijkmans, B. A. C.
    Gordon, K.
    Lovell, D.
    Panaccione, R.
    Perez, J.
    Pangan, A. L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (12) : 1863 - 1869
  • [2] de Mattos ABN, 2023, Brazil J Case Rep., V3, P12, DOI [10.52600/2763-583X.bjcr.2023.3.2.12-15, DOI 10.52600/2763-583X.BJCR.2023.3.2.12-15]
  • [3] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
    Feagan, B. G.
    Sandborn, W. J.
    Gasink, C.
    Jacobstein, D.
    Lang, Y.
    Friedman, J. R.
    Blank, M. A.
    Johanns, J.
    Gao, L. -L.
    Miao, Y.
    Adedokun, O. J.
    Sands, B. E.
    Hanauer, S. B.
    Vermeire, S.
    Targan, S.
    Ghosh, S.
    de Villiers, W. J.
    Colombel, J. -F.
    Tulassay, Z.
    Seidler, U.
    Salzberg, B. A.
    Desreumaux, P.
    Lee, S. D.
    Loftus, E. V., Jr.
    Dieleman, L. A.
    Katz, S.
    Rutgeerts, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) : 1946 - 1960
  • [4] Review article: anti TNF-α induced psoriasis in patients with inflammatory bowel disease
    Fiorino, G.
    Allez, M.
    Malesci, A.
    Danese, S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (09) : 921 - 927
  • [5] Association of Psoriasis With Inflammatory Bowel Disease A Systematic Review and Meta-analysis
    Fu, Yun
    Lee, Cheng-Han
    Chi, Ching-Chi
    [J]. JAMA DERMATOLOGY, 2018, 154 (12) : 1417 - 1423
  • [6] Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
    Guerra, Ivan
    Algaba, Alicia
    Lazaro Perez-Calle, Jose
    Chaparro, Maria
    Marin-Jimenez, Ignacio
    Garcia-Castellanos, Raquel
    Gonzalez-Lama, Yago
    Lopez-Sanroman, Antonio
    Mancenido, Noemi
    Martinez-Montiel, Pilar
    Quintanilla, Elvira
    Taxonera, Carlos
    Villafruela, Monica
    Romero-Mate, Alberto
    Lopez-Serrano, Pilar
    Gisbert, Javier P.
    Bermejo, Fernando
    [J]. JOURNAL OF CROHNS & COLITIS, 2012, 6 (05) : 518 - 523
  • [7] Guidelines of care for the management of psoriasis and psoriatic arthritis Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    Menter, Alan
    Korman, Neil J.
    Elmets, Craig A.
    Feldman, Steven R.
    Gelfand, Joel M.
    Gordon, Kenneth B.
    Gottlieb, Alice B.
    Koo, John Y. M.
    Lebwohl, Mark
    Lim, Henry W.
    Van Voorhees, Abby S.
    Beutner, Karl R.
    Bhushan, Reva
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 61 (03) : 451 - 485
  • [8] Puig Lluis, 2018, Curr Probl Dermatol, V53, P49, DOI 10.1159/000479475
  • [9] Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    Crowley, Jeffrey J.
    Ryan, Caitriona
    Krueger, James G.
    Tsai, Tsen-Fang
    Flack, Mary
    Gu, Yihua
    Williams, David A.
    Thompson, Elizabeth H. Z.
    Paul, Carle
    [J]. LANCET, 2019, 394 (10198) : 576 - 586
  • [10] Adverse effects of biologics: a network meta-analysis and Cochrane overview
    Singh, J. A.
    Wells, G. A.
    Christensen, R.
    Ghogomu, Tanjong E.
    Maxwell, L.
    MacDonald, J. K.
    Filippini, G.
    Skoetz, N.
    Francis, D.
    Lopes, L. C.
    Guyatt, G. H.
    Schmitt, J.
    La Mantia, L.
    Weberschock, T.
    Roos, J. F.
    Siebert, H.
    Hershan, S.
    Lunn, M. P. T.
    Tugwell, P.
    Buchbinder, R.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02):
12